Nasdaq Welcomes Ra Pharmaceuticals Inc. (Nasdaq: RARX) to The Nasdaq Stock Market
October 27 2016 - 12:30PM
Ra Pharmaceuticals Inc. (Nasdaq:RARX), a clinical stage
biopharmaceutical company focusing on the development of
next-generation therapeutics for diseases of complement
dysregulation, visited the Nasdaq MarketSite in Times Square today
in celebration of its initial public offering (IPO) on The
Nasdaq Stock Market on October 26, 2016.
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/d59a5715-0c97-4d3d-a5e3-bb4d47a6045b
Ra Pharmaceuticals uses its proprietary peptide chemistry
Extreme Diversity™ platform to develop novel therapeutics for the
treatment of diseases that are caused by excessive or uncontrolled
activation of the complement system, which is a critical component
of the body’s immune system. The Company’s lead compound, RA101495,
is a self-administered subcutaneous injection that is entering
Phase 2 development for the treatment of paroxysmal nocturnal
hemoglobinuria, or PNH, a life-threatening blood disorder.
“Listing on Nasdaq is an important milestone for our Company
that we are very proud to have achieved,” said Douglas Treco,
Ph.D., Chief Executive Officer and Co-Founder of Ra Pharmaceuticals
Inc. “Nasdaq is home to many of the world’s most innovative
biotechnology companies, and we are honored to now be among them.
We look forward to executing on our clinical strategy in our quest
to create novel therapies for patients and value for our
shareholders.”
“Ra Pharmaceuticals is developing the next generation of
therapies to treat complex autoimmune diseases,” said Nelson
Griggs, Executive Vice President, Listing Services, Nasdaq. “As the
leading exchange for some of the world’s most successful life
sciences companies, we are proud to be the listing partner of Ra
Pharmaceuticals as they continue to develop therapies that will
improve the lives of people with these serious and sometimes
debilitating diseases.”
The information contained above is provided for informational
and educational purposes only, and nothing contained herein should
be construed as investment advice, either on behalf of a particular
security or an overall investment strategy. Information about the
company is provided by the company or comes from the company’s
public filings and is not independently verified by Nasdaq.
Neither Nasdaq nor any of its affiliates makes any recommendation
to buy or sell any security or any representation about the
financial condition of any company. Statements regarding
Nasdaq-listed companies are not guarantees of future performance.
Actual results may differ materially from those expressed or
implied. Past performance is not indicative of future results.
Investors should undertake their own due diligence and carefully
evaluate companies before investing. ADVICE FROM A SECURITIES
PROFESSIONAL IS STRONGLY ADVISED.
About NasdaqNasdaq (Nasdaq:NDAQ) is a leading
provider of trading, clearing, exchange technology, listing,
information and public company services across six continents.
Through its diverse portfolio of solutions, Nasdaq enables
customers to plan, optimize and execute their business vision with
confidence, using proven technologies that provide transparency and
insight for navigating today's global capital markets. As the
creator of the world's first electronic stock market, its
technology powers more than 70 marketplaces in 50 countries, and 1
in 10 of the world's securities transactions. Nasdaq is home to
more than 3,700 listed companies with a market value of
approximately $9.3 trillion and more than 18,000 corporate clients.
To learn more, visit: nasdaq.com/ambition or
business.nasdaq.com
- NDAQG -
Media Relations Contacts:
Stephanie Lowenthal
(646) 441-5073
Stephanie.Lowenthal@nasdaq.com
Emily Pan
(646) 441-5120
emily.pan@nasdaq.com
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Apr 2023 to Apr 2024